XSHG
603387
Market cap607mUSD
Jul 10, Last price
8.28CNY
1D
1.97%
1Q
-18.74%
IPO
-9.71%
Name
Getein Biotech Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Getein Biotech, Inc. is an enterprise primarily focused on the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) solutions. Founded in 2002 and based in Nanjing, China, the company offers a comprehensive array of diagnostic products. This includes a variety of diagnostic reagents, advanced analytical instruments, and crucial calibrators. Getein also supplies foundational raw materials for reagents, such as monoclonal and polyclonal antibodies, antigens, antiserum, and microspheres. Its extensive product line caters to diverse medical fields, encompassing diagnostics for cardiac markers, inflammatory conditions, renal function, blood coagulation, thyroid disorders, fertility assessments, diabetes care, and thrombus detection. These offerings broadly serve applications in cardiovascular, inflammatory, diabetes, reproductive, renal, hepatic, and other key health areas.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||